Evidence map›Paper›PMID 38376788›Full record

ArticleDigestive diseases and sciences2024

Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.

Danny Con, Steven Tu, Daniel Clayton-Chubb, John S Lubel, Amanda J Nicoll, Rohit Sawhney, Stephen Bloom

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Danny ConDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia. dannycon302@gmail.com.
Steven TuDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia.
Daniel Clayton-ChubbDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia.
John S LubelDepartment of Gastroenterology, Alfred Health, Melbourne, VIC, Australia.
Amanda J NicollDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia.
Rohit SawhneyDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia.
Stephen BloomDepartment of Gastroenterology, Eastern Health, Box Hill Hospital, 8 Arnold Street, Box Hill, 3128, Melbourne, VIC, Australia.
Eastern Health · AUMonash University · AUBox Hill Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsConcurrent hepatic steatosis has diverse effects on chronic hepatitis B (CHB), however the combined effects of metabolic dysfunction-associated steatotic liver disease (MASLD) and CHB on liver fibrosis progression remains unclear. The primary aim of this study was to utilize serial fibrosis measurements to compare the dynamic change in fibrosis in CHB patients with/without concurrent MASLD. The secondary aim was to investigate factors associated with steatosis development and regression in CHB patients.

methodsThis was a retrospective cohort study of all non-cirrhotic CHB patients identified from 1/1/2011 to 31/12/2016. Hepatic steatosis was diagnosed by ultrasound. Fibrosis markers included liver stiffness (LSM) by transient elastography, APRI and FIB-4. General linear mixed effects modelling was used to fit polynomial and linear estimates.

resultsOf 810 CHB patients (n = 2,373 LSM measurements; median age 44.4y; 48% male; 24% HBeAg positive), 14% had concurrent MASLD. LSM was higher at baseline but decreased in MASLD patients over time, while LSM remained stable in non-MASLD patients, such that all patients had similar LSM beyond 4-5 years. MASLD patients had lower APRI compared to non-MASLD patients, which was predominately due to a higher platelet count and higher ALT over time. There was substantial discordance between LSM, APRI and FIB-4. Baseline BMI was the only factor that predicted steatosis development and regression.

conclusionsWe found no evidence of an association between concurrent MASLD and fibrosis progression amongst CHB patients without baseline advanced liver disease. APRI and FIB-4 may have reduced accuracy in MASLD patients.

Indexed as

Elasticity Imaging TechniquesFatty LiverHepatitis B, ChronicNon-alcoholic Fatty Liver DiseaseAdultFemaleHumansLiver CirrhosisMaleRetrospective StudiesCHBElastographyFatty liverHBVKineticsLiver stiffnessLSMMAFLDNAFLDNon-alcoholicSteatosis

Identifiers

PMID38376788
OpenAlexW4391955902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.